Company Overview and News
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front.
VVUS GLENMARK 532296 LGNZZ LGND LGNYZ LGNXZ LGNDZ BMRN GLKQY
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.
VVUS GLENMARK DB 532296 JNJ LGNZZ LGND LGNYZ LGNXZ LGNDZ BMRN GLKQY
Chicago, IL – June 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Illumina, Inc. (ILMN - Free Report) , Athersys, Inc. (ATHX - Free Report) , EyePoint Pharmaceuticals, Inc. (EYPT - Free Report) , Rhythm Pharmaceuticals, Inc.
NTLA EYPT UAA JBLU ILMN RYTM LGNDZ UA BRK.A ATHX LGNZZ LGND LGNYZ DG LGNXZ
Kitov Pharma Ltd. (KTOV - Free Report) announced today that the FDA has approved Consensi (amlodipine and celecoxib) oral tablets for the treatment of osteoarthritis pain and hypertension.
LGNZZ LGND LGNYZ LGNXZ HZNP PFE LGNDZ
Shares of Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) rose almost 8.2%, after the company announced that the FDA has accepted the new drug application (NDA) for its lead pipeline candidate, Firdapse, and granted Priority Review to the same. The FDA has set an action date of Nov 28, 2018.
CPRX ELY LGNZZ LGND LGNYZ LGNXZ ILMN LGNDZ BMRN
Melinta Therapeutics, Inc. (NASDAQ:MLNT) has 62 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 16,653,082 shares. Largest shareholders include Vatera Holdings Llc, Chelsea Counsel Co, Commonwealth Equity Services, Inc, Group One Trading, L.p., and Group One Trading, L.p.. Melinta Therapeutics, Inc.
LGNZZ LGNYZ LGND FH LGNXZ MLNT LGNDZ XSPA
Allergan plc (AGN - Free Report) announced a nationwide recall of some sample packs of Taytulla softgel oral contraceptive capsules (1mg/20mcg). Allergan said that four non-hormonal placebo pills were erroneously placed where the contraceptive capsules should have been. This instigated the recall following a physician report on the same.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ LGNDZ BMRN WFC.PRT WFC.PRR WFC.PRQ WFC.PRP AGN WFC.PRO WFC.PRN LGNZZ LGND LGNYZ LGNXZ WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Shares of Prothena Corporation (PRTA - Free Report) were down 1.62% a day after the company announced a reorganization plan. Prothena’s stock has lost 67.3% in the last six months, worse than the industry’s decline of 7.8%.
DUKH LGNZZ CELG LGND LGNYZ LGNXZ DUK LGNDZ
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with SWEDISH ORPHAN (SWTUY - Free Report) and Ligand Pharmaceuticals (LGND - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
LGNZZ LGND LGNYZ LGNXZ ISRG LGNDZ TLRD
Dr. Reddy's Laboratories Ltd. (RDY - Free Report) reported fourth-quarter fiscal 2018 earnings per American Depositary Share (ADS) of 28 cents, down 3.5% from 29 cents earned in the year-ago quarter.
ENTA PVH RDY LGNZZ LGND LGNYZ LGNXZ UTX ILMN LGNDZ
Shares of Allergan plc (AGN - Free Report) have declined 4.4% since it reported its first-quarter 2018 results on Apr 30. In fact, so far this year, Allergan’s share price has declined 5.3%, compared with the industry’s decline of 6.8%.
AMGN TOL AGN LGNZZ LGND LGNYZ LGNXZ LGNDZ
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET